

Recombinant Human VAP-1/AOC3 Protein (His Tag)

Catalog Number: PKSH032744

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	HEK293 Cells-derived Human VAP-1;AOC3 protein Arg28-Asn763, with an C-terminal His
Calculated MW	82.6 kDa
Observed MW	90-110 kDa
Accession	Q16853
Bio-activity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Concentration	Subject to label value.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation	Supplied as a 0.2 µm filtered solution of 20mM Tris-HCl, 500mM NaCl, pH 8.0.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Vascular adhesion protein-1(VAP-1) is a copper amine oxidase with a topaquinone cofactor. VAP-1 is a type II integral membrane protein; but a soluble form of the enzyme is present in human serum; and its level increases in diabetes and some inflammatory liver diseases. VAP-1 catalyzes the oxidative deamination of small primary amines such as methylamine; benzylamine; and aminoacetone in a reaction that produces an aldehyde; ammonia; and H₂O₂. VAP-1 vascular expression is regulated at sites of inflammation through its release from intracellular granules in which the protein is stored. The adhesive function of VAP-1 has been demonstrated in studies showing that the protein is important for the adherence of certain lymphocyte subtypes to inflamed endothelial tissues. VAP-1 mediated adhesion is involved in the process of leukocyte extravasation; an important feature of inflammatory responses. VAP-1 is considered to be a therapeutic target for diabetes; oxidative stress; and inflammatory diseases.

For Research Use Only